Stroke Research

Stroke is classified as both a neurological and a cardiovascular disease, as it is a disruption in blood supply to the brain which causes the neurological abnormalities. There are two types of stroke; ischemic and hemorrhagic.

Stroke Research Products Targets

Products for Stroke Research - Page 15

Cat.No. Product Name Information/Activity
BCC6266 LP 20 hydrochloride 1386928-34-2
BCC7161 2-Chloro-N6-cyclopentyladenosine Potent, selective A<sub>1</sub> agonist
BCC7160 N6-Cyclopentyladenosine N6-Cyclopentyladenosine (CPA) is a selective Adenosine A1 receptor agonist, with Ki values of 2.3 nM, 790 nM and 43 nM for human A1, A2A and A3 receptors, respectively.
BCC7716 (±)-5'-Chloro-5'-deoxy-ENBA Highly selective A<sub>1</sub> agonist
BCC7215 GR 79236 GR79236 is a highly potent and selective adenosine A1 receptor agonist (Ki = 3.1 nM) that has analgesic and anti-inflammatory actions in humans and animals.
BCC7311 2'-MeCCPA 205171-12-6
BCC7374 SDZ WAG 994 130714-47-5
BCC6664 1,3-Dipropyl-8-phenylxanthine 85872-53-3
BCC6649 DPCPX 102146-07-6
BCC6124 KW 3902 Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450). Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases.